{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-080409","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2026-07-02T21:01:00+00:00","discovered_at":"2026-07-02T21:04:00.651195+00:00","generated_at":"2026-07-02T21:04:16.905393+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Iovance updates corporate presentation; guides FY26 revenue $350M-$370M, Q2 $86M-$88M","bullets":["Q2 2026 revenue guidance of $86M-$88M; FY26 revenue guidance $350M-$370M; ~45% YoY quarterly growth.","Amtagvi commercial launch: >90 treatment centers, >1,500 patients treated; 5-year durability data: 31.4% ORR, 19.7% OS.","Lifileucel in NSCLC: 25.6% ORR, mDOR not reached at 25.4 months; Fast Track Designation; potential launch 2H27.","Soft tissue sarcoma Phase 2 registrational trial to commence 2Q 2026; 50% ORR in early data.","Cash $319M as of 3/31/26; manufacturing capacity up to 5K patients/year; broad payer coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-080409","json":"https://secwatch.observer/filing/0001104659-26-080409.json","markdown":"https://secwatch.observer/filing/0001104659-26-080409.md","text":"https://secwatch.observer/filing/0001104659-26-080409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926080409/0001104659-26-080409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926080409/tm2618989d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-02T21:04:16.905393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}